Pharmacalogical management of obesity

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorMbamali, Afoamakachukwu Adaeze
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptKenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2016-09-16T08:42:21Z
dc.date.available2016-09-16T08:42:21Z
dc.date.created2015-05-15
dc.description.abstractObesity is now an epidemic. The whole world which includes the developed and developing countries is grappling with the adverse effects of obesity. The creation of anti- obesity drugs has been a gigantic stride in the combat against obesity. Chapter 1 of my thesis briefly defines obesity, body mass index and methods used in the identification of obese individuals. In that same chapter, the WHO classification of obesity was also given. The epidemiology, pathogenesis and genetics of obesity were also discussed. I also dealt with the energy balance equation. There were also figures to expatiate further on the pathogenesis of obesity. In chapter 2, I highlighted the simulation of orlistat, sibutramine and their effects on inducing weight loss. I also looked at their side effects and orlistat’s drug interactions. Two figures were also attached in my chapter to give a simplified summary of the effects of the drugs. In chapter 3, I talked about rimonabant their effects, the few clinical trials that were conducted and their side effects. I also talked about a few novel drugs used in the treatment of obesity. Their side effect profile was also included in that chapter. In chapter 4, I talked about the herbal treatment of obesity and how they should be used as a complement to the colloquial pharmaceutical drugs. I also briefly talked about the nonpharmacological treatment of obesity, their importance and their contraindication. Chapter 5, was my closing chapter. It only contained my epilogue.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent35hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/230498
dc.language.isoenhu_HU
dc.rightsNevezd meg! 2.5 Magyarország*
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/hu/*
dc.subjectobesityhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titlePharmacalogical management of obesityhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)